Production (Stage)
Rapid Dose Therapeutics Corp.
RDTCF
$0.1393
-$0.0407-22.61%
OTC PK
| 02/28/2025 | 11/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 28.11% | -3.19% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 28.11% | -3.19% | |||
| Cost of Revenue | 42.75% | 22.59% | |||
| Gross Profit | 15.57% | -17.95% | |||
| SG&A Expenses | 25.53% | 7.22% | |||
| Depreciation & Amortization | 19.14% | -4.63% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 27.37% | 10.06% | |||
| Operating Income | -27.01% | -18.03% | |||
| Income Before Tax | -18.48% | -23.52% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -18.48% | -23.52% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -18.48% | -23.52% | |||
| EBIT | -27.01% | -18.03% | |||
| EBITDA | -29.75% | -19.44% | |||
| EPS Basic | -16.25% | -23.08% | |||
| Normalized Basic EPS | -16.00% | -21.95% | |||
| EPS Diluted | -16.25% | -23.08% | |||
| Normalized Diluted EPS | -16.00% | -21.95% | |||
| Average Basic Shares Outstanding | 1.27% | 0.86% | |||
| Average Diluted Shares Outstanding | 1.27% | 0.86% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||